February 8, 2013

Bernard Spots a New Insulin Pump Approval in FDA Docs: the Pearl

OK we d-geeks can be like bird spotters looking for prey in the thickets. So props to my pal Bernard who spotted what sure looks like FDA clearance for the Asante Pearl, a new insulin pump in the wild of the FDA's latest round of 510(k) announcements. 510(k) means something is substantially equivalent to some other approved device and this claims to be the equivalent of and Animas 1200 IR or a Disetronic D-TRONplus.

A screen grab off Asante's site shows Pearl looks like this:





I don't know much about it but this is what the company web site says:


The Pearl insulin pump is designed to make living every day with an insulin pump, easier. 
Filling a pump reservoir is an outdated process in today’s world. So we designed our insulin pump around a pre-filled insulin cartridge, a simple-to-use interface, a pump that primes itself as you assemble it, and occlusion detection designed to identify occlusions earlier. Not just fancier, but really, less work. 
The Pearl insulin pump has a durable controller and a replaceable pump body that, once assembled, functions as a "traditional" insulin pump. Just insert the prefilled cartridge into the replaceable pump body that simply clicks together with the controller, and off you go.
Half the work, half the time.

OK. There ya go.

Reservoirs are not on the top of my list of pump issues but Your Diabetes May Vary. I left a message for a PR guy and will pass on what I learn.

Kudos to Bernard for spotting the FDA announcement. 

Ryan Reed Racing with Roush Fenway and ADA

T1D NASCAR racer Ryan Reed was on Speed TV's Race Hub last night announcing he will be running a Mustang with Roush Fenway. The #16 sports American Diabetes Association colors.


(including more cool pictures) 



Diabetes Art Day Fans - A Favor Please?

I love diabetes art day. It's brilliant.

The good folks at the local news posted a web print story about it. Let's bury it with positive feed back. Make them want that kind of response again and maybe do an on air feature.




February 7, 2013

From The News Wire: New Children's Electronic Health Record Format Announced

From HealthIT.gov

New Children's Electronic Health Record Format Announced
A new database developed by the Agency for Healthcare Research and Quality with support from the Centers for Medicare and Medicaid Services can help software developers create better Electronic Health Records (EHRs) for the care of children. The children’s EHR format establishes a blueprint for EHRs to better meet the needs of health care providers and pediatric patients by combining best-practices in clinical care, information technology, and insights from experts in children’s health. Since few EHRs have been created with children’s needs in mind, gaps in functionality, data elements and other areas tend to occur. The format guides EHR developers in understanding the requirements for functionality, data standards, usability and interoperability of an EHR system to more optimally support the provision of health care to children – especially those enrolled in Medicaid or the Children’s Health Insurance Program (CHIP). The format is readily accessible and adoptable by EHR developers for use during product development or enhancement. 
In addition to providing guidance to developers, the format can provide guidance for EHR system purchasers and policy makers. For example, policy makers and purchasers can use the requirements when assessing functionality of EHRs. For more information or to access the format, select:http://healthit.ahrq.gov/childehrFormat

February 5, 2013

Joslin CEO John Brooks III on DSMA Live Rents


This episode of DSMA Live 'Rents  is an amazing conversation. Join Lorraine and I as we chat with (and are mesmerized by) a follow parent of a T1D child. It is clear the passion of a parent is a big part of what he does and that passion is also part of the history of Joslin.

A fellow d-dad John makes all us d-'Rents proud.

The show  is also available as a podcast from iTunes.

The after show write up:
http://diabetessocmed.com/2013/dsma-live-rents-afterthoughts-john-brooks-iii/


February 4, 2013

Diabetes Art Day 2013

Today is Diabetes Art Day.

Take some time, create something.

This year my contribution is called Two.





















Twice the fun. 

February 3, 2013

Josh's "Possible Cures for Type-1 in the News (Early Feb)"

It is that time.

Time to recommend reading Josh Levy. Once again I find myself spellbound by his blog and cautiously optimistic. Optimistic not about any give treatment necessarily but about the level of research and diversity of approaches and that somewhere in all of it there may be better treatments, partial cures and maybe... cures.

This month Josh writes about Trial of Polyclonal Tregs. There are immune regulatory cells. The idea is they take these from a person, make a bunch more in the lab and put them back in hope of restoring increasing the regulatory balance and preserving beta cell function. 

Learning about that is cool enough but what sets Josh apart for me is the detail of his discussion. He considers what constitutes remission for researchers. It is not necessarily what we would thing as PWDs. For researchers is is using half the insulin than otherwise, not none. Also Josh has a discussion of the ethics of research and the participation of children in the studies. This matters if a study is looking at the early stages just after diagnosis as there are far fewer adults available with recently diagnosed T1D than kids. This is an important conversation and I am thrilled to see it brought up in thoughtful manner. 

There is also a conversation of clinical trials on the cocktail mix of Cyclosporine and Lansoprazole. One to stop the autoimmune attack and the other to improve beta cell production. 

Science matters, understanding it does too and I think Josh does a better job month in and month out at reporting on the science of cures than any other single source I know.  As is usually the case my summaries of his blog don't do it justice. The best way I can think to say thanks is to I highly recommend  clicking over and having a look for your self.

Oh and while you are there sign up for his email updates.

http://cureresearch4type1diabetes.blogspot.com/2013/02/possible-cures-for-type-1-in-news-early.html

February 1, 2013

From the News Wire: Tandem buys some Smith (Cosmo) Patents

From the press release:

Tandem Diabetes Care Acquires Select Patents and Patent Applications from Smiths Medical  

SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Tandem Diabetes Care, Inc. ("Tandem") announced today that it has acquired ownership from Smiths Medical ASD, Inc. of over 23 U.S. patents and patent applications relating to the treatment of diabetes. As part of this transaction, Tandem has also obtained a license to 28 other U.S. patents and patent applications owned by Smiths Medical. This license affords Tandem exclusive access to technologies useful for future product development in the field of ambulatory infusion pumps and related software and accessories for the treatment of diabetes. These patents and patent applications complement Tandem's growing portfolio of intellectual property related to the company's novel technologies PR Newswire (http://s.tt/1zfjY)

#TwoBits from @diaTribeNews: OmniPod CGM News, SLG2



Our good friends over at diaTribe have a new issues out and it is chock full of good stuff.





It is all great but two items caught my eye:

First interesting new about the path OmniPod is pursuing with CGM. diaTribe reports that the Pod people are working to a a signal integrated pod/cgm patch. Apparently not the Dexcom sensor but no sensor vendor is named. Very interesting and maybe disappointing to some Pod Dexcom users, YDMV.  See diaTribe for details.
http://diatribe.us/issues/51/new-now-next/2

Also at diaTribe® is a very good write up of the SLGT-2 drug for T2D from JnJ that will be called Invokana (aka canagliflozin.) The 'Tribe explains what the class of drug is and how it works. As mention in a previous YDMV post, I had the privilege of joining diaTribe editor Kelly Close in commenting to the FDA's at the public hearing on the drug and supporting patient support new and innovative options for T2D care. It is not yet in the market and of course talk with you care team about pros and cons.  Details, including stuff to brush up on before talking with your doc, are available at diaTribe. http://diatribe.us/issues/51/new-now-next/1

If you don't subscribe to diaTribe, you are missing out. Join here:



What if Health Care... #whatifhc

@SusannahFox has a new hash tag and we DOC folks should play along. What if Health Care... #whatifhc  Lets play and add #diabetes.

More here:

http://storify.com/SusannahFox/what-if-health-care

Here is my first:

#whatifhc viewed patient access to health data to help us self manage as an ethical imperative? #diabetes